Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 10/04/2026

    Lancet Countdown Europe: New Report on Health and Climate Change

    Europe’s dependence on fossil fuels is not only making the continent economically and politically vulnerable, it also has consequences for the population’s health. Growing air pollution, heat damage and the climate-related spread of infectious diseases are looming, warns the 2026 Europe Report of the Lancet Countdown on Health and Climate Change, which its co-directors are about to present to the public.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/lancet-countdown-europe-new-report-health-and-climate-change
  • Press release - 10/04/2026

    New study identifies clinically relevant changes in airway wall thickness in COPD and at-risk individuals

    A recent study published in the European Respiratory Journal provides important new insights into the early identification and monitoring of chronic obstructive pulmonary disease (COPD). The focus is on airway wall thickness as an imaging marker for structural remodeling processes in the lungs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-study-identifies-clinically-relevant-changes-airway-wall-thickness-copd-and-risk-individuals
  • Press release - 10/04/2026

    Vitamin B12 Found to Drive Inherited Behavioural Changes Across Generations

    A team of researchers from the Department of Integrative Evolutionary Biology at the Max Planck Institute for Biology Tübingen has discovered that vitamin B12 plays a key role in transmitting behavioural memories across generations. The study shows for the first time how a nutrient from the diet can, without altering the genome, influence behaviour over multiple generations.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vitamin-b12-found-drive-inherited-behavioural-changes-across-generations
  • Press release - 10/04/2026

    Molecular analyses could improve treatment options for a rare soft tissue tumor

    Desmoplastic small- and round-cell tumor is rare, aggressive, and difficult to treat. Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have comprehensively analyzed 30 tumors and identified potential personalized treatment options for nearly all patients. In some patients, new targeted approaches were able to halt the disease for a surprisingly long time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-analyses-could-improve-treatment-options-rare-soft-tissue-tumor
  • Photoimmunotherapy - 09/04/2026 Zu sehen ist in einer Fluoreszenz-Aufnahme unter dem Mikroskop runde Ansammlungen in blauer Farbe, die die Zellkerne darstellen und rote Signale dicht daneben, die die Konjugate darstellen, all´ das vor schwarzem Hintergrund.

    Switching off tumours with light: how photons can be used to target prostate cancer

    Prostate cancer is the most common cancer among men in Germany. Relapses and the harsh side effects of traditional treatments remain a major challenge, even with advanced surgical techniques. At the University of Freiburg, Dr. Wolf is pioneering the development of photoimmunotherapy. Photoimmunotherapy combines light, antibodies and a specialised dye to precisely target tumour cells - simultaneously 'waking up' the immune system.

    https://www.gesundheitsindustrie-bw.de/en/article/news/switching-tumours-light-how-photons-can-be-used-target-prostate-cancer
  • Press release - 09/04/2026

    “Positions, please!”

    For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that (BET) proteins help activate, so blocking BET proteins should slow tumor growth. In the lab, it often did. In patients, results were mostly disappointing: limited responses, significant side effects, and no clear way to predict which tumors would respond at all.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/positions-please
  • Press release - 07/04/2026

    No soft drink before the massage

    How does sugar affect relaxation exercises? A new study carried out by researchers from the University of Konstanz provides revealing insights into the connection between blood glucose and the autonomic nervous system: The intake of sugar counteracts relaxation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/no-soft-drink-massage
  • Press release - 07/04/2026

    The molecular research “booster” evolves: SIMPLAIX collaboration starts the next phase

    Computer simulations and Artificial Intelligence are the main pillars of the “SIMPLAIX” collaboration, initiated by the Heidelberg Institute for Theoretical Studies (HITS). Together with colleagues from Heidelberg University and Karlsruhe Institute of Technology, HITS researchers are addressing challenges in the simulation of biomolecules and molecular materials by pooling their expertise in multiscale computer simulation and machine learning.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-research-booster-evolves-simplaix-collaboration-starts-next-phase
  • Press release - 07/04/2026

    The molecular research “booster” evolves: SIMPLAIX collaboration starts the next phase

    Computer simulations and Artificial Intelligence are the main pillars of the “SIMPLAIX” collaboration, initiated by the Heidelberg Institute for Theoretical Studies (HITS). Together with colleagues from Heidelberg University and Karlsruhe Institute of Technology, HITS researchers are addressing challenges in the simulation of biomolecules and molecular materials by pooling their expertise in multiscale computer simulation and machine learning.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-research-booster-evolves-simplaix-collaboration-starts-next-phase
  • Press release - 02/04/2026

    Pocket-sized biomedical technology to become smarter Volkswagen Foundation supports mobile health expert Professor Walter Karlen

    The Volkswagen Foundation is supporting the Ulm scientist Professor Walter Karlen with more than 940,000 euros from the funding initiative "Momentum - funding for first-time researchers". The engineer has headed the Institute of Biomedical Engineering at Ulm University since 2021. Karlen conducts research in the field of mobile health on so-called Medicine Wearables, i.e. portable technology for recording health data.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pocket-sized-biomedical-technology-become-smarter-volkswagen-foundation-supports-mobile-health-expert-professor-walter-karlen
  • Press release - 01/04/2026

    Digital Assistance System Designed to Prevent Recurrent Heart Disease

    Women who have experienced a stroke or heart attack are at a higher risk of mortality than men. Fraunhofer researchers want to improve gender-specific aftercare with a customized assistance system – thus helping to prevent further heart disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/digital-assistance-system-designed-prevent-recurrent-heart-disease
  • Press release - 31/03/2026

    First steps towards cell therapy for brain disorders

    Researchers in Freiburg have found a way to selectively replace defective immune cells in the blood vessels of the brain using an animal model. This is an important first step towards cell therapies for Alzheimer’s disease and other brain disorders. The findings were recently published in the journal Nature Immunology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-steps-towards-cell-therapy-brain-disorders
  • Press release - 30/03/2026

    Ulm University funds projects on molecular quantum bits and digital diabetes research Research incubators focus on ideas outside the mainstream

    Creating scope for innovative projects from various disciplines: That is the aim of the research incubators at Ulm University. The aim is to initiate developments and ideas that could become relevant research areas for the University. In the current call for proposals, the jury has selected two interdisciplinary projects on quantum chemistry and digital, sensor-based diabetes research.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ulm-university-funds-projects-molecular-quantum-bits-and-digital-diabetes-research-research-incubators-focus-ideas-outside-mains
  • Event - 06/05/2025

    Symposium of the Biological Development Center - Accelerating Translation from Discovery to Application

    Reutlingen, Informationsveranstaltung
    https://www.gesundheitsindustrie-bw.de/en/event/symposium-biological-development-center-accelerating-translation-discovery-application
  • Proof-of-concept study of organoid technology - 26/03/2026 Smiling man with glasses wearing a white lab coat.

    Can organoids improve the treatment of pancreatic cancer?

    A clinical trial called UNITEPANC is exploring whether organoid-based approaches can improve the treatment of pancreatic cancer. BIOPRO Baden-Württemberg spoke with the study’s principal investigator and pancreatic cancer specialist, Prof. Dr. Thomas Seufferlein of University Hospital Ulm, to discuss the disease more broadly along with the specific aims of the trial. The interview was conducted by Walter Pytlik on behalf of BIOPRO.

    https://www.gesundheitsindustrie-bw.de/en/article/news/can-organoids-improve-treatment-pancreatic-cancer
  • Press release - 25/03/2026

    The Influence of Lymph Node Architecture on Lymphoma

    For the first time, researchers have succeeded in mapping the organization of immune cells in human lymph nodes. The study was led by scientists from Heinrich Heine University Düsseldorf, Düsseldorf University Hospital, the DKFZ, the European Molecular Biology Laboratory (EMBL), and the Max Delbrück Center (MDC) in Berlin. They were able to demonstrate why the architecture of healthy lymph nodes is altered in malignant lymphomas.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/influence-lymph-node-architecture-lymphoma
  • Press release - 24/03/2026

    Ovarian Cancer: Adipose Tissue Influences the Efficacy of Immunotherapy

    In ovarian cancer, immunotherapies using checkpoint inhibitors have so far been effective in only a small number of patients. Researchers at the HI-TRON Mainz* have now discovered that lipid metabolism processes in the tumor microenvironment play a decisive role in how well such therapies work. The findings open up new avenues for using immunotherapies in a more targeted manner, increasing their effectiveness, and overcoming resistance.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eierstockkrebs-fettgewebe-beeinflusst-wirksamkeit-der-immuntherapie
  • Press release - 23/03/2026

    Aggravated neuroimmune response, delayed wound healing Transcription factor NF-κB in astrocytes critically affects the outcome of traumatic brain injury (TBI)

    Traumatic brain injuries often lead to complications with long-lasting consequences on memory, concentration and movement control. Detrimental secondary inflammatory reactions at the injured tissue sites are often responsible for this. Researchers from Ulm have now shown that a transcription factor plays a key role in reactions to TBI. When this gene regulator is activated, an elevated neuroimmune response promotes inflammation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/aggravated-neuroimmune-response-delayed-wound-healing-transcription-factor-nf-kb-astrocytes-critically-affects-outcome-traumatic
  • Press release - 23/03/2026

    After a Heart Attack: Inflammation Weakens the Heart’s Energy Production

    Why does heart function often continue to deteriorate after a heart attack, even though blood flow has been restored? A research team from the DZHK sites Heidelberg and North has now identified an important mechanism: an inflammatory switch in cardiomyocytes can impair cellular energy production and thereby drive the development of heart failure. The results were published in Nature Communications.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/after-heart-attack-inflammation-weakens-hearts-energy-production
  • Press release - 23/03/2026

    New findings on the first steps in Protein Synthesis

    In the earliest phase of creating human proteins, the protein complex NAC performs an essential task by starting the first steps towards folding proteins into their correct three-dimensional structures. This discovery was made by an international research team led by scientists from the Center for Molecular Biology of Heidelberg University.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-first-steps-protein-synthesis
  • Press release - 19/03/2026

    New Approaches for Treatment-Resistant Disorders

    The German Center for Mental Health (DZPG) conducts nationwide research on individualized treatments for depression, anxiety disorders, and addiction. Its approach combines established therapeutic methods with innovative strategies to enhance overall treatment efficacy. The primary beneficiaries are patients for whom conventional therapies have so far proven insufficiently effective.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approaches-treatment-resistant-disorders
  • Press release - 19/03/2026

    Carl-Zeiss-Stiftung Funds Pioneering AI Project at the DKFZ

    How can artificial intelligence support medical imaging diagnostics in the future and significantly improve patient care? Researchers led by Lena Maier-Hein (German Cancer Research Center, DKFZ, and NCT Heidelberg) have developed an innovative concept to address this question. The Carl Zeiss-Stiftung is funding the MEDAL* project with a total of three million euros.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/carl-zeiss-stiftung-funds-pioneering-ai-project-dkfz
  • Press release - 19/03/2026

    How old are we really?

    Ageing is a highly individual process. An international consortium coordinated by researchers in Konstanz has developed a method that uses biomarkers to determine a person's biological age – a valuable tool for research on ageing and the development of new approaches in preventive medicine.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-old-are-we-really
  • Press release - 19/03/2026

    Psilocybin combined with psychotherapy shows significant efficacy in treatment-resistant depression

    The results of the EPIsoDE study show that psilocybin can have a significant antidepressant effect. It is important that its use be integrated into psychotherapeutic pre- and post-treatment care.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/psilocybin-combined-psychotherapy-shows-significant-efficacy-treatment-resistant-depression
  • Press release - 17/03/2026

    Targeting Cancer Drugs More Effectively: First EU Project Integrates Pharmacogenomics into Tumor Boards

    The Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology (IKP) at the Bosch Health Campus in Stuttgart is leading Europe’s first EU project to systematically integrate pharmacogenomics into molecular tumor boards (MTB). The goal of PGxMTB is to systematically incorporate patients’ genetic factors into treatment decisions, thereby making cancer therapies safer and more effective.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-cancer-drugs-more-effectively-first-eu-project-integrates-pharmacogenomics-tumor-boards

Page 1 / 37

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 37
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search